This accelerated delivery platform improves clinic workflow and speeds up breast cancer diagnosis and treatment planning. From screening mammogram, a clinical pathway flags patients who meet One-Stop Breast Clinic criteria, eliminating the traditional “first come, first served” scheduling model. To date, more than 300 patients have benefited from this rapid diagnostic approach, receiving their diagnosis in 3 to 7 days, far below the national average of 26 days.

Guest:

Michele Brands

Network Director Women's Imaging

St. Luke's University Health Network, St. Luke's Cancer Care

Bethlehem, Pennsylvania

Quote:

“[After COVID-19] access really became an issue for diagnostic breast imaging…the One-Stop Breast Clinic allows us to take our highest-risk patients…and get them from the diagnostic process through biopsy to pathology in 48 hours or less.”

Additional Resources:

Improving the Care of Patients Newly Diagnosed with Breast Cancer

Clinical Meaningfulness: Insights from a Metastatic Breast Cancer Qualitative Study

The Changing Landscape of Breast Cancer

Empowering Cancer Patients Using Integrative Medicine: A Novel Model for Breast Cancer Risk Modification

Breast Care ACCESS Project

Anemia presents a significant challenge in the management of patients with low-risk myelodysplastic syndromes (MDS). As clinicians focus on maintaining quality of life, it is necessary to understand the care sequencing of anemia treatment in patients with low-risk MDS. In this episode, CANCER BUZZ speaks with Steven Gilmore, PharmD, BCOP, Senior Manager of Clinical Content in Pharmacy and Clinical Programs with McKesson Specialty Health, and Christopher Benton, MD, hematologist and medical oncologist at Rocky Mountain Cancer Centers, to review key considerations and emerging trends for the treatment of anemia in the low-risk MDS population.

“Social determinants [are] an important element in terms of patient compliance...MDS is a disease that primarily affects older individuals. And sometimes this can be hard [for them], to make it into the clinic on a weekly or biweekly basis in order to get an injection of the ESA.”—Christopher Benton, MD

“Everyone on the health care team can contribute [to] the management of MDS—hematologist-oncologists…clinical pharmacists and APPs [advanced practice providers]…hematopathologists…dietitians and social workers—all of the expertise from these professionals leads to a holistic approach that addresses medical, psychosocial, and supportive care needs of the patient.”—Steven Gilmore, PharmD, BCOP

Christopher Benton, MD

Hematologist and Medical Oncologist

Rocky Mountain Cancer Centers

Denver, CO

Steven Gilmore, PharmD, BCOP

Senior Manager, Clinical Content, Pharmacy & Clinical Programs

McKesson Specialty Health

Baltimore, MD

This episode was developed in connection with the ACCC education initiative Anemia Mitigation & Optimal Care for MDS Patients and is supported by Bristol Myers Squibb.

Resources:

ACCC Myelodysplastic Syndromes

ASH 2020 Treatment Algorithm Lower-Risk MDS

This AI-driven incidental findings program identifies and then monitors pancreatic abnormalities to improve the quality of care to patients who are at increased risk for developing pancreatic cancer. To do so, the patient management software integrates with the electronic health record and facilitates patient identification, risk assessment, care plan tracking, patient and provider communication, outcomes recording, and registry functionality. In the 2 years following program implementation, 82 pancreatic cancers were detected from incidental findings with 65% of patients being diagnosed in earlier stages (stages I, II, and II), as well as instances of ampullary cancer, gallbladder cancer, and gastric cancer.

Guest:

Russell Langan, MD, FACS, FSSO

Associate Chief Surgical Officer, System Integration and Quality & Director of Surgical Oncology

RWJBarnabas Health, Rutgers Cancer Institute of New Jersey, Cooperman Barnabas Medical Center

Livingston, New Jersey

“There remains a knowledge gap with respect to the risk associated with pancreatic cysts. Many patients are identified to have a pancreatic cyst on an incidental scan and then told [by providers] that there’s no risk. [Some] patients will then return years later with pancreatic cancer. And it’s very unfortunate because we know that risk could have been addressed when it was in its precancerous state.” —Russell Langan, MD, FACS, FSSO

Hear more about this innovation at the ACCC 41st National Oncology Conference, October 9-11, 2024, in Minneapolis, Minnesota. Register today.

Additional Resources:

Reimagining Healthcare for Incidental Lung Nodules

Oncology Capture of ED Patients with Incidental Radiologic Findings

Pancreatic Cancer and Community Engagement: A Scoping Review of the Literature

Let’s Win Pancreatic Cancer: A Partner for Patients and Care Teams